MedTrace Logo

Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)

NCT00617123 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2018-09-21

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).

Conditions

Interventions

DRUG

Vorapaxar 2.5 mg

Vorapaxar 2.5 mg oral tablet

DRUG

Placebo

matching placebo oral tablet

Sponsors & Collaborators

  • The TIMI Study Group

    collaborator OTHER

  • Duke Clinical Research Institute

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-01
Primary Completion
2010-10-01
Completion
2010-10-01

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00617123 on ClinicalTrials.gov